Inferior outcomes in immunocompromised Merkel cell carcinoma patients: Can they be overcome by the use of PD1/PDL1 inhibitors?
| العنوان: | Inferior outcomes in immunocompromised Merkel cell carcinoma patients: Can they be overcome by the use of PD1/PDL1 inhibitors? |
|---|---|
| المؤلفون: | Steven C. Plaxe, David M Hyams, Constantin A Dasanu, Michael Del Rosario, Ion Codreanu |
| المصدر: | Journal of Oncology Pharmacy Practice. 25:214-216 |
| بيانات النشر: | SAGE Publications, 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | Male, Oncology, medicine.medical_specialty, Skin Neoplasms, animal structures, Programmed Cell Death 1 Receptor, Antineoplastic Agents, Antibodies, Monoclonal, Humanized, B7-H1 Antigen, Avelumab, Immunocompromised Host, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Azathioprine, medicine, Advanced disease, Humans, Immunologic Factors, Pharmacology (medical), Stage (cooking), skin and connective tissue diseases, Aged, Retrospective Studies, Aged, 80 and over, integumentary system, Merkel cell carcinoma, business.industry, Incidence (epidemiology), Antibodies, Monoclonal, virus diseases, Cancer, Immunosenescence, Middle Aged, medicine.disease, Carcinoma, Merkel Cell, Treatment Outcome, 030220 oncology & carcinogenesis, Cohort, Female, business, 030215 immunology, medicine.drug |
| الوصف: | Cases of Merkel cell carcinoma have become increasingly more common in the last two decades, and its incidence has been predicted to climb further. Immunosenescence might explain in part the higher Merkel cell carcinoma prevalence in seniors aged 70 and older. This cancer might also be more aggressive in immunocompromised patients. In a subset of immunocompromised Merkel cell carcinoma patients, we identified significant lymphopenia and a more advanced disease stage compared with their immunocompetent counterparts. Time to death in this cohort was much shorter than in immunocompetent subjects, and their likelihood of death from Merkel cell carcinoma was five times higher. Avelumab approval in 2017 represents an important step forward in the therapy of Merkel cell carcinoma. Hopefully, PD1/PDL1 inhibitors will improve survival in immunocompromised Merkel cell carcinoma hosts, traditionally linked with inferior clinical outcomes. |
| تدمد: | 1477-092X 1078-1552 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05efab1639b5bb68456319341af62ba8Test https://doi.org/10.1177/1078155218785002Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....05efab1639b5bb68456319341af62ba8 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 1477092X 10781552 |
|---|